A novel GPI-anchored dominant-negative TGF-β receptor II renders T cells unresponsive to TGF-β signaling

Transforming growth factor β (TGF-β) is a pleiotropic cytokine expressed by a wide range of cell types and is known for hampering the effectiveness of cancer immune cell therapeutic approaches. We have designed a novel construct containing the extracellular domain of the TGF-β receptor II linked to...

Descripción completa

Detalles Bibliográficos
Autores principales: Petersen, Sven H., Al Badawy, Kays, Hopkins, Richard, Vu, Dang L., Rahmani, Mehran, Maia, Sonia M.P., Connolly, John E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565558/
https://www.ncbi.nlm.nih.gov/pubmed/37829123
http://dx.doi.org/10.1016/j.omto.2023.100730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565558/
https://www.ncbi.nlm.nih.gov/pubmed/37829123
http://dx.doi.org/10.1016/j.omto.2023.100730

Ejemplares similares